Immunic Inc. (IMUX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 4, 2022 6:30 AM EDTInitial Clinical Activity Results of IMU-935 in Psoriasis Expected in the Fourth Quarter
Unblinded Safety Data from the Single and Multiple Ascending Dose Parts of Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects Expected in the Third Quarter
$88.1 Million in Cash and Cash Equivalents Expected to Fund Immunic Into the Fourth Quarter of 2023
Webcast to be Held Today, August 4, 2022, at 8:00 am ET
NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq:... More
